Abzena PLC | Balance Sheet

Fiscal year is April-March. All values GBP Thousands.
2014
2015
2016
2017
2018
Cash & Short Term Investments
2,757.00
15,799.00
13,724.00
4,135.00
6,785.00
Total Accounts Receivable
1,750.00
4,308.00
7,005.00
5,256.00
10,916.00
Inventories
295.00
817.00
1,379.00
1,876.00
1,939.00
Other Current Assets
1,054.00
-
-
-
-
Total Current Assets
5,856.00
20,924.00
22,108.00
11,267.00
19,640.00
Net Property, Plant & Equipment
693.00
1,490.00
4,170.00
7,612.00
11,514.00
Intangible Assets
9,446.00
8,942.00
23,177.00
25,882.00
23,135.00
Total Assets
16,030.00
31,356.00
49,455.00
44,761.00
54,289.00
ST Debt & Current Portion LT Debt
-
-
-
169.00
213.00
Accounts Payable
400.00
2,354.00
5,488.00
1,419.00
2,105.00
Income Tax Payable
-
-
-
178.00
157.00
Other Current Liabilities
878.00
-
362.00
4,553.00
4,428.00
Total Current Liabilities
1,278.00
2,354.00
5,850.00
6,319.00
6,903.00
Long-Term Debt
-
-
-
494.00
448.00
Deferred Taxes
1,183.00
1,153.00
2,031.00
2,014.00
1,649.00
Other Liabilities
-
-
518.00
-
1,600.00
Total Liabilities
2,496.00
3,507.00
8,399.00
8,827.00
10,600.00
Common Equity (Total)
13,534.00
27,849.00
41,056.00
35,934.00
43,689.00
Total Shareholders' Equity
13,534.00
27,849.00
41,056.00
35,934.00
43,689.00
Total Equity
13,534.00
27,849.00
41,056.00
35,934.00
43,689.00
Liabilities & Shareholders' Equity
16,030.00
31,356.00
49,455.00
44,761.00
54,289.00

About Abzena

View Profile
Address
Babraham Research Campus
Cambridge Cambridgeshire CB22 3AT
United Kingdom
Employees -
Website http://abzena.com/
Updated 09/14/2018
Abzena Plc engages in the provision of proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products. It operates through the following segments: Biology, Chemistry, and Biomanufacturing. Its services include: antibody discovery and candidate screening; immunology and immunogenicity assessment; antibody and protein engineering to reduce immunogenicity; and custom synthesis of cytotoxic payloads, reagents, and other small molecules.